Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty Drugsmeridian Axitinib (Inlyta) Coverage & Prior Auth |…
    Ask Trek AI about this page
    CurrentmeridianPolicy MDN.CP.PHAR.100

    Axitinib (Inlyta) — Coverage and Prior Authorization

    Customize your policy alerts

    Sign up for meridian Policy MDN.CP.PHAR.100 alerts

    Get alerted when Policy MDN.CP.PHAR.100 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity criteria, prior authorization requirements, and approval durations for axitinib (Inlyta) for Medicaid members, including FDA-approved and selected off-label indications and continuation criteria.

    Policy Summary
    Payermeridian
    PolicyAxitinib (Inlyta) — Coverage and Prior Authorization
    Policy CodePolicy MDN.CP.PHAR.100
    Change TypeNo material changes
    Effective DateDec 1, 2024
    Last ReviewNov 6, 2024
    Next Review DateNov 6, 2024
    Key ActionObtain prior authorization and submit clinical documentation (diagnosis, oncologist involvement, age, dosing justification, and supporting evidence for off‑label use) demonstrating the member meets all approval criteria.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    6 monthsinitial approval (Medicaid)
    12 monthscontinued therapy (Medicaid)
    20 mgmax daily dose
    ≥18minimum age

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    1 mg, 5 mgavailable strengths
    5references

    Coverage Criteria and Authorization Rules

    inv-05: Other diagnoses/indications — Covered when ONE of the following is met

    Covered when ONE of the following is met

    Other indications rule: 1. If the drug has had a label change within the last 6 months not yet reflected in this policy, route request per: (a) CP.PMN.255 (no coverage criteria) for drugs on the PDL (Medicaid), or (b) CP.PMN.16 (non-formulary) for drugs not on the PDL (Medicaid); OR 2. If the requested use (diagnosis, age, dosing) is NOT specifically listed under Section III and criterion 1 does not apply, refer to the off-label use policy CP.PMN.53 (Medicaid).

    Provides routing to other policies for coverage determination.

    inv-04: Continuation Therapy — All Indications in Section I — Covered when ALL of the following are met

    Covered when ALL of the following are met

    Continuation criteria: 1. Member is currently receiving Inlyta via the Centene benefit, or documentation supports current receipt of Inlyta for a covered indication with at least 30 days of therapy; 2. Member is responding positively to therapy; 3. If request is for a dose increase, the request meets one of the following: (a) new dose does not exceed 20 mg (4 tablets) per day; OR (b) new dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence).20 mg/day

    Prescribed regimen must be FDA-approved or recommended by NCCN. Approval duration for continued therapy (Medicaid): 12 months.

    Non‑FDA approved indications that are not specifically addressed in this policy are not authorized for coverage unless the provider supplies sufficient documentation of efficacy and safety in accordance with the Health Plan's off‑label use requirements (see policy CP.PMN.53 for Medicaid) or evidence of coverage documents.

    Treatment requests for indications that are not FDA‑approved and not listed in this policy will be considered not authorized unless the request includes adequate supporting clinical evidence per the applicable off‑label use policy (CP.PMN.53) or other evidence of coverage documentation demonstrating efficacy and safety for the requested use.

    Where state Medicaid requirements or provisions conflict with this clinical policy, the state Medicaid coverage provisions take precedence. Providers must follow applicable state and federal requirements and the member's coverage documents when requesting coverage.

    Coding and Dose Limits

    Maximum daily dose
    Maximum daily dose20 mg/day
    Typical single-agent dosing (RCC)5 mg orally twice daily (see prescribing information)
    Combination therapy dosing noteUsed with avelumab 800 mg q2w or pembrolizumab 200 mg q3w (per regimen tables)
    Axitinib (Inlyta) — quantity/limit
    Quantity/limit (Axitinib - Inlyta)20 mg per day maximum
    Common dosing formTablets: 1 mg and 5 mg available (see Appendix/References)
    Request requirement

    Provider Responsibilities and Authorization Procedures

    Prior Authorization

    Prior authorization required — document diagnosis, oncology involvement, age, and dosing

    Prior authorization is required for Inlyta. The provider must document the member's diagnosis, that the drug was prescribed by or in consultation with an oncologist, the member is age ≥ 18 years, and that the requested dose does not exceed 20 mg per day or is supported by practice guidelines/peer‑reviewed literature for off‑label use (prescriber must submit supporting evidence).

    • Diagnosis must match the applicable criteria (e.g., relapsed/metastatic/stage IV RCC; DTC; alveolar soft part sarcoma).
    • Oncologist involvement or consultation must be documented.
    • Dose must be ≤ 20 mg/day or supported by literature with evidence submitted.
    Note

    Formulary exception review for Marketplace members

    Requests for non‑formulary agents for Health Insurance Marketplace members must be evaluated under the plan's formulary exception process; coverage is only available when the agent is on the health plan approved formulary or approved via the formulary exception policy.

    Definitions and Reference Terms

    DTC (Differentiated thyroid carcinoma)
    Definition (DTC)Differentiated thyroid carcinoma: follicular, oncocytic/Hurthle cell, or papillary thyroid carcinoma
    Use in policyCovered as an off-label indication when specific criteria are met (see Initial Therapy — DTC)
    Related guidanceFailure of sorafenib (Nexavar) required for DTC indication unless contraindicated
    RCC (Renal cell carcinoma)
    Definition (RCC)Renal cell carcinoma
    Policy contextCovered for relapsed, metastatic, or stage IV RCC when criteria are met (age ≥18, oncology involvement, dosing limits)

    Background and Drug Information

    Axitinib (Inlyta) is an oral tyrosine kinase inhibitor indicated for advanced renal cell carcinoma. It is used as combination therapy with checkpoint inhibitors (avelumab or pembrolizumab) in the first‑line setting and as a single agent for advanced RCC after one prior systemic therapy. Product strengths available include tablets: 1 mg and 5 mg, and dosing should not exceed a maximum of 20 mg per day unless supported by practice guidelines or peer‑reviewed literature submitted by the prescriber.

    Step Therapy and Therapeutic Alternatives

    StepRequirementNotes / therapeutic alternatives
    1Use or documented failure of alternative systemic therapies or participation in clinical trials considered prior to approval.Appendix B lists therapeutic alternatives including pazopanib (Votrient), sunitinib (Sutent), cabozantinib (Cabometyx), everolimus (Afinitor), sorafenib (Nexavar), bevacizumab (Avastin), nivolumab (Opdivo), temsirolimus (Torisel), lenvatinib (Lenvima), and others.

    Quantity Limits and Dosing Caps

    Axitinib (Inlyta) — quantity/limit
    Quantity limit20 mg per day maximum for Axitinib (Inlyta)
    Unitmg per day
    Dose justificationPolicy requires doses above 20 mg/day to be supported by practice guidelines or peer-reviewed literature with prescriber documentation

    Criteria for Continued Therapy

    Revision History and References

    References: 1. Inlyta Prescribing Information. Pfizer Labs, Inc.; September 2022. Additional sources cited in policy development include the NCCN Drugs & Biologics Compendium, NCCN guidelines for Kidney Cancer and Thyroid Carcinoma, and the Clinical Pharmacology database. This policy was adapted from IL.PHAR.100 and approved by Meridian Health Plan with documentation of reference sources listed in the policy's reference section.

    Policy Summary
    Payermeridian
    PolicyAxitinib (Inlyta) — Coverage and Prior Authorization
    Policy CodePolicy MDN.CP.PHAR.100
    Change TypeNo material changes
    Effective DateDec 1, 2024
    Last ReviewNov 6, 2024
    Next Review DateNov 6, 2024
    Key ActionObtain prior authorization and submit clinical documentation (diagnosis, oncologist involvement, age, dosing justification, and supporting evidence for off‑label use) demonstrating the member meets all approval criteria.
    SourceLink
    On This Page
    Coverage Criteria and Authorization RulesCoding and Dose LimitsProvider Responsibilities and Authorization ProceduresDefinitions and Reference TermsBackground and Drug InformationStep Therapy and Therapeutic AlternativesQuantity Limits and Dosing CapsCriteria for Continued TherapyRevision History and References
    Dose increases above 20 mg/day require guideline or peer-reviewed literature support and prescriber evidence
    • Follow the formulary exception policy for Marketplace members when the requested drug is non‑formulary.
    Step Therapy

    Step therapy / alternatives — consider listed systemic therapies; Nexavar failure required for DTC

    Therapeutic alternatives listed in Appendix B (e.g., pazopanib, sunitinib, cabozantinib, everolimus, sorafenib, lenvatinib) should be considered; for the DTC off‑label indication, failure of sorafenib (Nexavar) is required unless contraindicated or adverse effects occur.

    • Appendix B lists alternative systemic therapies and dosing considerations.
    • DTC: document failure or contraindication to Nexavar (sorafenib) when applicable.
    Note

    Alert — verify prior authorization for combination and off‑label regimens

    Providers should note that prior authorization may be required for combination regimens (e.g., with pembrolizumab or avelumab) and for off‑label uses; confirm authorization requirements when submitting requests.

    • Combination therapy for RCC (with Keytruda®/Bavencio®) and ASPS (with Keytruda®) may require prior authorization.
    Documentation Required

    Required clinical documentation — submit chart notes, labs, and supporting evidence

    Submit supporting clinical documentation with the prior authorization request, such as office chart notes, laboratory results, or other clinical information demonstrating the member meets all approval criteria.

    • Include evidence supporting off‑label use when applicable (practice guidelines or peer‑reviewed literature).
    Billing Rule

    Follow coverage documents and legal/regulatory requirements

    Providers must follow the member's coverage documents (evidence of coverage, certificate of coverage, policy) and applicable state and federal requirements when requesting coverage; this policy guides medical necessity but does not override contractual or legal obligations.

    • Coverage decisions are subject to the terms, conditions, exclusions and limitations of the coverage documents and applicable law.
    Denial Risk

    Denial risk — off‑label uses require sufficient supporting evidence

    Requests for non‑FDA approved indications not addressed in this policy may be denied unless sufficient documentation of efficacy and safety is provided per the off‑label use policy (CP.PMN.53) or the member's evidence of coverage.

    • When seeking coverage for off‑label indications, submit clinical evidence demonstrating efficacy and safety as required by off‑label policy.
    Note

    Coverage subject to contract terms and legal requirements

    Coverage decisions and benefit administration are governed by the member's coverage documents and applicable legal/regulatory requirements; discrepancies are controlled by law and plan contractual terms.

    • This clinical policy is a guide to medical necessity and does not guarantee payment.
    Therapeutic regimens
    Single-agent or in combination with pembrolizumab or avelumab for clear cell histology
    Inlyta Prescribing Information (Pfizer, Sept 2022)
    Reference titleInlyta Prescribing Information (Pfizer, September 2022)
    Source URLFDA label available via accessdata.fda.gov (see References)
    Use in policyPrescribing information cited as reference for dosing and safety information